Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Aldhaheri (Kingston, Canada), O. Moran-Mendoza (Kingston, Canada), L. Mccarthy (Kingston, Canada). Clinical impact of an interstitial lung disease Nurse on patients with idiopathic pulmonary fibrosis. 5240

Member's Comments

No comment yet.

Related content which might interest you: Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Clinical features of usual interstitial pneumonia-correlation between idiopathic pulmonary fibrosis and connective tissue disease associated with usual interstitial pneumonia Source: International Congress 2016 – Connective tissue disorders Year: 2016 Clinical characteristics and survival in patients with idiopathic pulmonary fibrosis with and without associated emphysema Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Comparison between patients with idiopathic pulmonary fibrosis and patients with pulmonary involvement of the usual interstitial pneumonia pattern that preceded the onset of rheumatoid arthritis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Diagnostic utility of surgical lung biopsies in elderly patients with interstitial lung diseases Source: International Congress 2015 – New insights into IIPs Year: 2015 Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Baseline characteristics and survival of patients with pulmonary hypertension in interstitial lung disease in the “HYPID” study Source: Annual Congress 2013 –Pulmonary circulation: clinical physiology Year: 2013 Clinical profile of idiopathic pulmonary fibrosis with lung cancer Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease Source: International Congress 2015 – New insights into IIPs Year: 2015 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016